biotech. pharmaceutical. business english

China’s game-changing pharmaceutical and biotech industry | 364

Brief

China is fast becoming a major player in the global pharmaceutical and biotech industries. Once focused primarily on generic and me-too drugs, Chinese companies are now making headlines with innovative breakthroughs in oncology and gene therapy. Foreign investors are taking notice, pouring billions into partnerships and research projects across the country. But can China maintain this momentum — or will political pressure and consumer skepticism slow things down?

Overview

In this episode of Down to Business English, Skip Montreux and Dez Morgan explore how China’s pharmaceutical and biotech sectors are reshaping the global healthcare landscape. They trace the industry’s evolution from state-run factories to world-class R&D centers, discuss the surge in foreign investment, and introduce key players like Akeso Biopharma. Along the way, they also unpack some of the challenges that may lie ahead for this fast-growing industry.

Insights 

Skip and Dez discuss China’s pharmaceutical boom while helping you expand your business English skills. Key takeaways include:

  • The difference between pharmaceuticals and biotech — and where they overlap.
  • The rise of Chinese firms like Akeso Biopharma and their potential to rival Western Big Pharma.
  • Key challenges facing the sector, including domestic reputation issues and foreign policy risk.

In summary 

D2B 364 investigates China’s pharmaceutical transformation — from copycat drugs to cutting-edge therapies — and asks what it means for the future of global medicine and investment trends.

Do you like what you hear?

Become a D2B Member today for access to our interactive audio scripts, bonus Down to Vocabulary, and Member-only D2B episodes.

For full access to the Interactive Audio Player, .

Be sure to follow to D2B on your favorite podcast client!!

Listen on Apple Podcasts

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top